Sign in
CompletedNo phase

Serum Neurofilament Light Chain Levels and Neuropathy Severity in Diabetic Polyneuropathy

Key facts

Who runs it
Kanuni Sultan Suleyman Training and Research Hospital
Where
Türkiye1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
88 people enrolled
Started
25 Mar 2026
Ended
30 Jun 2026
Type of study
Observational, 2 groups
Treatments tested
  • Blood Sample Collection and Clinical Assessment
Record updated
20 August 2026

Who can take part

Age
30 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • For the DPN+ group:
  • Presence of diabetic polyneuropathy confirmed by clinical examination, Michigan Neuropathy Screening Instrument (MNSI), and nerve conduction studies
  • For the DPN- group:
  • Type 2 diabetes mellitus without clinical or electrophysiological evidence of diabetic polyneuropathy

Who cannot take part

  • Neuropathy due to causes other than diabetes (e.g., vitamin B12 deficiency, hypothyroidism, alcohol abuse, chemotherapy) Renal dysfunction (eGFR < 60 mL/min/1.73 m²) Active infection or malignancy Inflammatory or autoimmune neurological diseases Central nervous system disorders (e.g., stroke, multiple sclerosis) Lumbar radiculopathy or peripheral entrapment neuropathy Severe visual impairment or balance disorders affecting testing Pregnancy Cognitive impairment preventing completion of questionnaires Patients with isolated small fiber neuropathy without electrophysiological evidence of large fiber involvement

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Diabetic polyneuropathy (DPN) is one of the most common chronic complications of diabetes mellitus and is characterized by peripheral nerve damage caused by long-term hyperglycemia. Progressive sensory loss and impairment of proprioception may lead to balance disturbances, gait instability, and an increased risk of falls. Neurofilament Light Chain (NfL) has emerged as a potential biomarker of neuroaxonal injury in several neurological disorders.

Read full original descriptionShow less

The aim of this observational cross-sectional study is to investigate the relationship between serum Neurofilament Light Chain (NfL) levels and neuropathy severity, balance performance, and fall risk in patients with diabetic polyneuropathy. Neuropathy severity will be evaluated using the Michigan Neuropathy Screening Instrument (MNSI) and electrophysiological findings, while balance performance and fall risk will be assessed using the Berg Balance Scale and the Falls Efficacy Scale-International (FES-I).

The 2 groups in the trial

  • Diabetic Polyneuropathy (DPN+)

    Participants with Type 2 diabetes mellitus diagnosed with diabetic polyneuropathy based on clinical examination, the Michigan Neuropathy Screening Instrument (MNSI), and electrophysiological evaluation using nerve conduction studies.

    Treatment: Blood Sample Collection and Clinical Assessment

  • Diabetic Control (DPN-)

    Participants with Type 2 diabetes mellitus without clinical or electrophysiological evidence of diabetic polyneuropathy who will serve as the control group.

    Treatment: Blood Sample Collection and Clinical Assessment

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Association Between Serum Neurofilament Light Chain (NfL) Levels and Neuropathy Severity, Balance Performance, and Fall Risk in Diabetic Polyneuropathy
Publications
Record updated
20 August 2026